Study details
Enrolling now
18F-Fluciclovine PET Imaging in Brain Cancer Patients After Stereotactic Radiosurgery
Baptist Health South Florida
NCT IDNCT06048094ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
46
Study length
about 3.1 years
Ages
18+
Locations
1 site in FL
What this study is about
This trial is testing if 18F-fluciclovine PET imaging can help doctors see how well brain cancer treated with stereotactic radiosurgery (SRS) responds to treatment. The goal is to determine if 18F-fluciclovine PET imaging can be used as a biomarker to measure response or progression of brain metastasis after SRS.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take 18F fluciclovine
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
fluciclovine (18F)
Endpoints
Primary: Change in Standardized Uptake Value (SUV)-peak